Humasis Co. Ltd. (KOSDAQ:205470)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,000.00
-36.00 (-3.47%)
Jan 30, 2026, 3:30 PM KST
-42.53%
Market Cap113.15B -41.2%
Revenue (ttm)35.60B +114.9%
Net Income-37.58B
EPS-364.96
Shares Out113.15M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,006,868
Average Volume1,058,677
Open1,036.00
Previous Close1,036.00
Day's Range1,000.00 - 1,042.00
52-Week Range923.00 - 1,945.00
Beta0.06
RSI46.59
Earnings DateMar 13, 2026

About Humasis

Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women’s health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface proteins, COVID-19 RT-PCR kit, and COVID-19 Variant RT-qPCR kit, as well as MPXV real time PCR kit, a real-time polymerase chain reaction assay for the quali... [Read more]

Industry Medical - Equipment & Services
Sector Healthcare
Founded 2000
Employees 69
Stock Exchange KOSDAQ
Ticker Symbol 205470
Full Company Profile

Financial Performance

In 2024, Humasis's revenue was 25.41 billion, an increase of 83.79% compared to the previous year's 13.83 billion. Losses were -30.44 billion, -45.08% less than in 2023.

Financial Statements